Gastrointestinal tumors are a leading cause of mortality worldwide. As shown in our previous study, miR-1290 is overexpressed in colorectal cancer (CRC) and promotes tumor progression. We therefore aimed to explore the potential of circulating miR-1290 as a biomarker for gastrointestinal cancer. A serum miRNA sequencing analysis was performed. Then, circulating miRNA detection technologies were established. The expression of miR-1290 was analyzed in gastrointestinal tumor cell lines and culture supernatants. Expression levels of circulating miR-1290 in clinical samples were examined. Associations between miR-1290 expression and clinicopathologic characteristics were analyzed. Xenograft models were generated to assess the fluctuation in serum miR-1290 levels during disease progression. Through miRNA sequencing, we identified that miR-1290 was overexpressed in serum samples from patients with CRC. We confirmed that human gastrointestinal tumor cells express and secrete miR-1290. The circulating miR-1290 levels was up-regulated in patients with pancreatic cancer (PC) (p < 0.01), CRC (p < 0.05), and gastric cancer (GC) (p < 0.01). High miR-1290 expression levels were associated with tumor size, lymphatic invasion, vascular invasion, distant metastasis, tumor differentiation and AJCC stage in patients with PC and CRC. The area under the curve (AUC) was 0.8857 in patients with PC, with 60.9% sensitivity and 90.0% specificity. The AUC was 0.7852 in patients with CRC, with 42.0% sensitivity and 90.0% specificity. In patients with GC, the AUC was 0.6576, with 26.0% sensitivity and 90.0% specificity. The in vivo model verified that the circulating miR-1290 level was significantly increased after tumor formation and decreased after drug treatment. Our findings indicate that circulating miR-1290 is a potential biomarker for gastrointestinal cancer diagnosis and monitoring.

中文翻译：

---

循环 MiR-1290 作为人类胃肠道肿瘤的潜在诊断和疾病监测生物标志物

胃肠道肿瘤是世界范围内导致死亡的主要原因。正如我们之前的研究所示，miR-1290 在结直肠癌 (CRC) 中过度表达并促进肿瘤进展。因此，我们旨在探索循环 miR-1290 作为胃肠癌生物标志物的潜力。进行血清miRNA测序分析。然后，建立了循环miRNA检测技术。在胃肠道肿瘤细胞系和培养上清液中分析了 miR-1290 的表达。检查了临床样品中循环 miR-1290 的表达水平。分析了 miR-1290 表达与临床病理特征之间的关联。生成异种移植模型以评估疾病进展期间血清 miR-1290 水平的波动。通过miRNA测序，我们发现 miR-1290 在 CRC 患者的血清样本中过表达。我们证实人类胃肠道肿瘤细胞表达和分泌 miR-1290。在胰腺癌 (PC) (p < 0.01)、CRC (p < 0.05) 和胃癌 (p < 0.01) 患者中，循环 miR-1290 水平上调。miR-1290的高表达水平与PC和CRC患者的肿瘤大小、淋巴浸润、血管浸润、远处转移、肿瘤分化和AJCC分期相关。PC 患者的曲线下面积 (AUC) 为 0.8857，敏感性为 60.9%，特异性为 90.0%。CRC 患者的 AUC 为 0.7852，敏感性为 42.0%，特异性为 90.0%。在 GC 患者中，AUC 为 0.6576，敏感性为 26.0%，特异性为 90.0%。体内模型证实，肿瘤形成后循环miR-​​1290水平显着升高，药物治疗后降低。我们的研究结果表明，循环 miR-1290 是胃肠道癌症诊断和监测的潜在生物标志物。